CXCR Inhibitors

CXCR

CXCR1

CXCR2

CXCR3

CXCR4

CXCR7

CXCR6

CXCR Inhibitors, Agonists, Antagonists, Activators & Modulators

Product Name	CXCR	CXCR1	CXCR2	CXCR3	CXCR4	CXCR7	CXCR6	Purity
Plerixafor					¹²⁵I-CXCL12-CXCR4, IC₅₀: 44 nM			99.90%
SB225002			¹²⁵I-IL-8-CXCR2, IC₅₀: 22 nM (in CHO cell membrane)					99.87%
AMG 487				¹²⁵I-IP10-CXCR3, IC₅₀: 8 nM ¹²⁵I-ITAC-CXCR3, IC₅₀: 8.2 nM				99.80%
Reparixin		CXCR1^wt, IC₅₀: 5.6 nM (in L1.2 cells) CXCR1^Ile43Val, IC₅₀: 80 nM (in L1.2 cells) CXCR1, IC₅₀: 1 nM (in cells)	CXCR2, IC₅₀: ∼100 nM (in cells)					99.99%
Plerixafor octahydrochloride					¹²⁵I-CXCL12-CXCR4, IC₅₀: 44 nM			99.09%
Peptide R TFA					CXCR4			98.34%
Navarixin		Cynomolgus CXCR1, Kd: 41 nM ¹²⁵I-CXCL8-CXCR1, IC₅₀: 43 nM	Mouse CXCR2, Kd: 0.2 nM Rat CXCR2, Kd: 0.2 nM Cynomolgus CXCR2, Kd: 0.08 nM ¹²⁵I-CXCL8-CXCR2, IC₅₀: 0.97 nM					99.33%
Rugocrixan			¹²⁵I-IL-8-CXCR2, Ki: 2800 nM (in HEK293S cells)					99.54%
AZD-5069			¹²⁵I-IL-8-CXCR2					99.91%
Motixafortide					CXCR4, IC₅₀: ~1 nM			99.88%
TAK-779				mCXCR3, IC₅₀: 369 nM (in PBMCs)				99.89%
ACT-1004-1239						CXCR7		98.81%
Baohuoside I					CXCR4			99.94%
Mavorixafor trihydrochloride					¹²⁵I-SDF-CXCR4, IC₅₀: 13 nM			99.75%
ML339							CXCR6, IC₅₀: 140 nM	99.88%
SX-682		CXCR1	CXCR2					99.67%
NUCC-390 dihydrochloride					CXCR4			98.19%
LY2510924					¹²⁵I-SDF-1α-CXCR4, IC₅₀: 79.7 pM ¹²⁵I-SDF-1α-CXCR4, Ki: 49.5 pM			99.11%
SB-265610			CXCR2					≥99.0%
SCH 546738				Human CXCR3, Ki: 0.4 nM				98.71%
IT1t dihydrochloride					CXCL12/CXCR4, IC₅₀: 2.1 nM			99.77%
VUF11207 fumarate						CXCR7, pKi: 8.1		98.50%
Reparixin L-lysine salt		CXCR1^wt, IC₅₀: 5.6 nM (in L1.2 cells) CXCR1^Ile43Val, IC₅₀: 80 nM (in L1.2 cells) CXCR1, IC₅₀: 1 nM (in cells)	CXCR2, IC₅₀: ∼100 nM (in cells)					99.87%
CXCR7 antagonist-1						CXCR7		99.85%
Danirixin			CXCL8-CXCR2, IC₅₀: 12.5 nM					98.88%
CAY10594			CXCR2					98.64%
NBI-74330				[¹²⁵I]CXCL10-CXCR3, Ki: 1.5 nM (in CXCR3-CHO cell membranes) [¹²⁵I]CXCL11-CXCR3, Ki: 3.2 nM (in CXCR3-CHO cell membranes)				99.76%
Ulocuplumab					CXCR4			99.90%
ACT-777991				CXCR3				99.86%
Nicotinamide N-oxide			CXCR2					99.85%
PS372424 hydrochloride				Human CXCR3				≥98.0%
Balixafortide TFA					CXCR4, IC₅₀: <10 nM			99.78%
WZ811					CXCR4, EC₅₀: 0.3 nM			99.80%
TC14012					CXCR4, IC₅₀: 19.3 nM (antagonist site)	CXCR7, EC₅₀: 350 nM (agonist site)		98.92%
Cosalane			CXCR2, IC₅₀: 0.66 μM					99.78%
Elubrixin tosylate			CXCR2					99.78%
Ladarixin sodium		CXCR1	CXCR2					99.84%
CTCE-0214					SDF-1α-CXCR4			98.94%
SX-517		CXCR1	CXCR2					99.88%
SCH 563705		CXCR1, Ki: 3 nM CXCR1, IC₅₀: 7.3 nM	CXCR2, Ki: 1 nM CXCR2, IC₅₀: 1.3 nM Mouse CXCR2, IC₅₀: 5.2 nM					99.86%
CXCR2 antagonist 8			CXCR2					99.24%
Burixafor hydrobromide					CXCR4			≥98.0%
AMD 3465 hexahydrobromide					12G5 mAb-CXCR4, IC₅₀: 0.75 nM (in SupT1 cells) CXCL12^AF647-CXCR4, IC₅₀: 18 nM (in SupT1 cells)			≥98.0%
CXCR2-IN-2		CXCR1, IC₅₀: 3.8 μM	CXCR2, IC₅₀: 5.2 nM					99.52%
MSX-122					CXCR4/CXCL12, IC₅₀: ~10 nM			98.92%
CXCR2-IN-1			CXCR2, pIC₅₀: 9.3					99.54%
CXCR7 antagonist-1 hydrochloride						CXCR7		99.41%
FC131 TFA					¹²⁵I-SDF-1-CXCR4, IC₅₀: 4.5 nM			99.89%
CXCR7 modulator 2						CXCR7, Ki: 13 nM		98.71%
CTCE-9908					CXCR4			99.47%
AMD 3465					12G5 mAb-CXCR4, IC₅₀: 0.75 nM (in SupT1 cells) CXCL12^AF647-CXCR4, IC₅₀: 18 nM (in SupT1 cells)			99.59%
USL311					CXCR4			99.97%
LIT-927					CXCL12/CXCR4, Ki: 267 nM			99.86%
ALX 40-4C Trifluoroacetate					SDF-1-CXCR4, Ki: 1 μM
UNBS5162	CXCL							98.10%
AZD8309			CXCR2, IC₅₀: 4 nM					99.98%
CXCR7 modulator 1						CXCR7, Ki: 9 nM		99.50%
ACT-660602				CXCR3, IC₅₀: 204 nM				99.86%
EPI-X4					CXCR4, IC₅₀: 8.6 μM			99.21%
AMG 487 (S-enantiomer)				CXCR3				99.94%
CXCR3 antagonist 1				CXCR3, IC₅₀: 0.06 μM				98.6%
MSX-127					CXCR4			99.68%
NUCC-390					CXCR4			98.40%
SRT3190			CXCR2					99.77%
Elubrixin			CXCR2
Mavorixafor hydrochloride					¹²⁵I-CXCL12-CXCR4, IC₅₀: 13 nM			99.10%
FC131					¹²⁵I-SDF-CXCR4, IC₅₀: 4.5 nM
IT1t					CXCL12/CXCR4, IC₅₀: 2.1 nM
CXCR4-IN-3					CXCR4, IC₅₀: 3.2 nM			99.69%
KRH-3955 hydrochloride					SDF-1α-CXCR4, IC₅₀: 0.61 nM
Peptide R					CXCR4
PS372424				Human CXCR3
ALX 40-4C					SDF-1-CXCR4, Ki: 1 μM
MSX-130					CXCR4			98.00%
Mavorixafor					¹²⁵I-SDF-CXCR4, IC₅₀: 13 nM
Ac-Pro-Gly-Pro-OH			CXCR2					99.49%
VUF11207						CXCR7, pKi: 8.1
SRT3109			CXCR2, pIC₅₀: 8.2					99.82%
Balixafortide					CXCR4, IC₅₀: <10 nM
CXCR4 antagonist 3					CXCR4, IC₅₀: 11 nM
CXCR2 antagonist 6			CXCR2, IC₅₀: 0.43 μM
CXCR4 antagonist 1					CXCR4
AZ10397767			CXCR2, IC₅₀: 1 nM
ICT5040					CXCR4, IC₅₀: 3.8 μM
CXCR2 antagonist 7			CXCR2, IC₅₀: 0.044 μM
SCH-900875		CXCR1	CXCR2	CXCR3
TC14012 TFA					CXCR4, IC₅₀: 19.3 nM (antagonist site)	CXCR7, EC₅₀: 350 nM (agonist site)
CXCR4 antagonist 4					CXCR4, IC₅₀: 24 nM
Corydalmine			CXCR2
CXCR4 antagonist 8					CXCR4, IC₅₀: 57 nM
CXCR4 modulator-2					CXCR4, IC₅₀: 1.25 nM
CXCR4 antagonist 6					CXCR4, IC₅₀: 79 nM
CXCR2 antagonist 4			CXCR2, IC₅₀: 0.13 μM
VUF11207 TFA						CXCR7, pKi: 8.1
CXCR4 antagonist 7					CXCR4/CXCL12, IC₅₀: 9.3 nM
CXCR4 antagonist 5					CXCR4, IC₅₀: 8.8 nM
CTCE-9908 TFA					CXCR4
HF50731					CXCR4, IC₅₀: 19.8 nM
RCP168					CXCR4, IC₅₀: 5 nM
CXCR4 modulator-1					CXCR4, EC₅₀: 100 nM
VUF11418			CXCR2
TIQ-15					CXCR4, IC₅₀: 6 nM
BC-1485		CXCR1
CCX662						CXCR7
BAM-12P						CXCR7, EC₅₀: 175 nM
CXCR2 antagonist 5			CXCR2, IC₅₀: 0.013 μM
Nicotinamide N-oxide (Standard)			CXCR2
Hit 14					12G5 mAb-CXCR4, IC₅₀: 254 nM
CXCR4 antagonist 9					CXCR4, IC₅₀: 15 nM
CXCR4 antagonist 10					CXCR4, IC₅₀: 7.8 nM
KRH-1636					CXCR4
ATI-2341					CXCR4, EC₅₀: 194 nM (in CCRF-CEM cells)

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4